title: Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument.
abstract: OBJECTIVE
  To analize the influence that maximal androgen blockade (MAB) exerts on quality of life in patients from the health area of Zamora diagnosed of prostate adenocarcinoma between 2000-2005.
  
  
  METHODS
  Basal, 12-month, 24-month and 36-month application of the health-related quality of life measurement instrument EORTC QLQ-PR25 to the population sample (n= 111), as well as a control sample (n= 100). We performed a comparative study of the outcomes between groups; between various time measurements in MAB patients; and inter-categories/ intervals of some variables in patients with hormonal deprivation therapy (third year of follow-up).
  
  
  RESULTS
  Cognitive and symptomatic fields were affected in patients with MAB at some specific time points. No field showed a significant constant worsening through the period of study for hormonally deprivated patients. A recovery is seen in the sociofamiliar field. Less academic level in MAB patients represents a distinguishing factor leading to worse outcomes in the health-related quality of life parameters analyzed here.
  
  
  CONCLUSIONS
  There is a negative initial repercussion of MAB on quality of life, although tinged according to the different fields studied.
authors.affiliation: Department of Urology, Complejo Asistencial de Zamora, Zamora, España. ncruz_g@hotmail.com
authors.forename: Nicolás Alberto
authors.initials: NA
authors.lastname: Cruz Guerra
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D000726:Androgen Antagonists